Zytoprotec Completes Phase I/II Trial of Novel Dialysate, Enters Into Negotiations with Global Pharmaceutical Company
B3C newswire, 05/24/2012
Zytoprotec, a company developing drugs based on active cytoprotection, announced the completion of a Phase I/II clinical trial with its lead product, PD–protec. The product is developed to improve the treatment of patients with kidney failure.



